Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage
Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early afternoon trading.